Richard Adam Messmann MD

Summary

• Dr. Richard Messmann is a medical oncologist, biochemist, electrical and computer engineer and clinical research physician with over 25 years of experience in oncology drug development ranging from Phase I-III clinical studies. Dr. Messmann’s career focus is in the development of targeted diagnostic and therapeutic agents for treatment of various cancer indications.
  
  After completing a medical oncology fellowship at the National Cancer Institute and obtaining an advanced degree in clinical trial management from Duke University, he served as Deputy Associate Director of the NIH/NCI’s Developmental Therapeutics Program (DTP). He has also held executive positions with Advanced Accelerator Applications (AAA, Novartis AG), Endocyte, Eli Lilly & Co., Michigan State University, ProNAi Therapeutics, Apexian Pharmaceuticals and Amgen Inc.
  
  Dr. Messmann's clinical leadership of the VISION Phase 3 study of Pluvicto (177Lu-PSMA-617) resulted in the regulatory approval of the first successfully developed radio-therapeutic and radio-diagnostic for use in men with advanced metastatic castrate-resistant prostate cancer. The trial results were presented at the ASCO 2021 plenary session with a concurrent publication in the New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/nejmoa2107322).
  
  He is currently the Executive Medical Director for Global Development of Xaluritamig (AMG 509), an Anti-STEAP1 XmAb 2+1 T-cell therapy against advanced-stage prostate cancer, early details of which were presented at the 2023 Madrid meeting of the European Society of Medical Oncology.